Biopharmaceutical Product Attributes and Biological Consequences Community

 View Only

Open Scientific Discussion - Relevance of Protein Aggregation in the Lung

  • 1.  Open Scientific Discussion - Relevance of Protein Aggregation in the Lung

    Community Leadership
    Posted 10-03-2025 15:36

    Please join this exciting AAPS Science360 Open Scientific Discussion on Relevance of Protein Aggregation in the Lung hosted by the Inhalation & Nasal Community (INC) and Biopharmaceutical Product Attributes and Biological Consequences (BPABC) Community on Thursday, 16 October 2025, 12:30 PM US EST / 18:30 CET

    Speaker / Discussion Leader: Markus Fridén (Senior Director, AstraZeneca)

    Registration Link

    Brief Description:

    The delivery of inhaled protein therapeutics has long been viewed as a promising approach, yet very few of these treatments have successfully reached the market. One of the persisting challenges has been concerns over the potential risks posed by protein aggregates in aerosol formulations, specifically the possibility that these aggregates may trigger undesirable immunological responses. Aggregation can be caused by protein unfolding at the air-water interface present during nebulization, or through dehydration processes such as spray-drying in dry powder formulations. As a result, rigorous quality assessments of aerosol products typically include evaluations for higher molecular weight species using chromatographic methods and analyses for insoluble particles. 

    This discussion will explore the current understanding of how protein aggregates may influence immune responses, with particular attention to their formation and fate within the complex environments of the lung. It examines available evidence regarding the in vivo detection of aggregates, as well as the link between aggregate presence and immunogenicity. Drawing on these insights, the talk will also highlight emerging strategies and considerations for developing bio-relevant aggregate testing methods tailored to inhaled biologics. We look forward to your participation in a lively discussion on this topic!

    Where: Register for the OSD using this link

    Please feel free to share meeting information with your colleagues who may be interested in this discussion.

    Thank you,

    INC and BPABC Leadership Teams



    ------------------------------
    Mayank Patel Ph.D.
    Senior Director
    AstraZeneca
    Gaithersburg MD
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------